The arrival of new oral antibiotics for uncomplicated urinary tract infection (uUTI) creates both opportunity and stewardship responsibility.1,2 Antimicrobial stewardship programs have consistently emphasized that therapeutic novelty alone does not justify broadened use; rather, novel agents should be positioned where they deliver distinct clinical value to preserve their long-term utility.3
For uUTI, newer agents represent meaningful additions to existing treatment options. When standard first-line therapy is contraindicated, not tolerated, or local resistance patterns reduce the likelihood of empiric success, these agents offer clinically appropriate alternatives that expand available options for patients who may otherwise have limited choices.2-4 Gepotidacin is indicated for individuals assigned female at birth who are aged 12 and older and weigh at least 88 lbs (40 kg), while pivmecillinam broadens the available oral options for patients where established agents are unsuitable.5 Notably, gepotidacin’s approved indications extend beyond uUTI to include uncomplicated urogenital gonorrhea in patients aged 12 years and older, reflecting its broader spectrum of activity.5 Patient-specific factors including renal function, allergy history, prior treatment response, and local antibiogram data remain central to selection across all available agents, whether established or newly approved.
Social determinants of health warrant consideration across all treatment decisions, as cost, insurance coverage, and pharmacy access can meaningfully influence whether a prescribed agent is obtained and completed regardless of which therapy is selected. For newer agents, access considerations such as formulary status, prior authorization requirements, and patient out-of-pocket costs may influence prescribing and treatment completion. The broader relationship between social determinants of health and antimicrobial resistance remains an underdeveloped area of research, with existing evidence highlighting gaps in understanding how upstream systemic inequalities, including those affecting marginalized populations such as individuals experiencing homelessness, rural communities, and displaced persons, shape antibiotic access, use, and resistance patterns.6 Strengthening this evidence base, with attention to drivers of health inequity rather than individual behaviors alone, represents an important frontier in stewardship research.6
Effective stewardship extends beyond agent selection to encompass the full arc of treatment, from prescribing through completion. The dual-target mechanism of gepotidacin, simultaneously inhibiting DNA gyrase and topoisomerase IV, is less susceptible to resistance from single target-site mutations, a biologic feature with potential stewardship implications. Urine culture and susceptibility testing remain the cornerstone of targeted therapy, but awareness that newer agents may not be included on standard susceptibility panels is an important consideration. The goal in integrating newer agents is not displacement of proven options, but extension of effective oral therapy as the resistance landscape continues to evolve, ensuring that clinicians and patients retain reliable choices in the years ahead.
Take our uUTI quiz to see how your knowledge compares to your peers.
